Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celularity Inc CELU

Financial Services Healthcare Biotechnology
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen... see more

Recent & Breaking News (NDAQ:CELU)

Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH)

GlobeNewswire February 2, 2023

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH)

GlobeNewswire February 1, 2023

Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates

GlobeNewswire January 26, 2023

Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia

Business Wire January 11, 2023

Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East

Business Wire January 11, 2023

Celularity's Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn's Disease in Phase 1, Phase 1b/2a and Phase 1b Studies

GlobeNewswire January 6, 2023

Celularity Appoints Paul Graves as Chief Communications Officer

GlobeNewswire January 4, 2023

Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model

Business Wire December 5, 2022

Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on "The Science and Technology for Extending Healthy Human Lifespan"

Business Wire November 30, 2022

Imugene's onCARlytics combination with Celularity's placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting

GlobeNewswire November 10, 2022

Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2022

Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer's 37th Annual Meeting

GlobeNewswire November 10, 2022

Celularity Promotes Two Executives in Executive Leadership Team

GlobeNewswire October 6, 2022

Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer

GlobeNewswire October 3, 2022

Celularity to Present at Jefferies Cell and Genetic Medicine Summit

GlobeNewswire September 27, 2022

Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

GlobeNewswire September 26, 2022

Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville

GlobeNewswire September 15, 2022

Celularity Announces Participation in Upcoming Investor Conferences

GlobeNewswire September 6, 2022

Celularity Reports Second Quarter 2022 Financial Results and Corporate Update

GlobeNewswire August 9, 2022

Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

GlobeNewswire July 27, 2022